payer perspective
Earn $300M Per Payor With Tirzepatide Vs Semaglutide
Tirzepatide can generate $300 million in net savings per 10,000 MC4R-deficient members, outpacing semaglutide’s $250 million, when formulary inclusion lowers hospitalizations and improves adherence. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health